Marianna Pinheiro Moraes de Moraes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marianna Pinheiro Moraes de Moraes has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Orlando Graziani Povoas Barsottini
Division of General Neurology and Ataxia Unit, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
10 shared publications - José Luiz Pedroso
Division of General Neurology and Ataxia Unit, Department of Neurology Universidade Federal de São Paulo São Paulo Brazil
9 shared publications - Fabiano Ferreira de Abrantes
Universidade Federal de São Paulo, Brazil
4 shared publications - Flávio Moura Rezende Filho
Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia, São Paulo SP, Brazil
4 shared publications - Victor Hugo Rocha Marussi
Hospital Beneficência Portuguesa de São Paulo, Divisão de Radiologia, São Paulo SP, Brazil
3 shared publications - Acary Souza Bulle Oliveira
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (07) , 001-014
A diagnostic approach to neurocutaneous syndromes
Neurocutaneous syndromes are a group of genetically and phenotypically diverse disorders that primarily affect the skin, central and peripheral nervous systems, and eyes. Classifying neurocutaneous syndromes based on genetic mechanisms often proves impractical in routine clinical settings. This review proposes a practical classification of neurocutaneous syndromes based on their neurological manifestations, including neoplastic lesions, epilepsy, vascular abnormalities, and ataxia. In this narrative review, we examined original articles and reviews that explore neurocutaneous syndromes, published between January 2000 and July 2024. The figures are part of a personal collection of the authors. Early recognition of dermatological and neurological hallmarks can guide diagnosis and prompt timely evaluation and treatment. Therefore, a thorough understanding of neurocutaneous syndromes highlights the importance of integrated diagnostic strategies that combine neurological and dermatological assessments.
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (07) , 001-014
Open AccessA diagnostic approach to neurocutaneous syndromes
Neurocutaneous syndromes are a group of genetically and phenotypically diverse disorders that primarily affect the skin, central and peripheral nervous systems, and eyes. Classifying neurocutaneous syndromes based on genetic mechanisms often proves impractical in routine clinical settings. This review proposes a practical classification of neurocutaneous syndromes based on their neurological manifestations, including neoplastic lesions, epilepsy, vascular abnormalities, and ataxia. In this narrative review, we examined original articles and reviews that explore neurocutaneous syndromes, published between January 2000 and July 2024. The figures are part of a personal collection of the authors. Early recognition of dermatological and neurological hallmarks can guide diagnosis and prompt timely evaluation and treatment. Therefore, a thorough understanding of neurocutaneous syndromes highlights the importance of integrated diagnostic strategies that combine neurological and dermatological assessments.
- Open Access
- 6 January 2025
- Published by Elsevier in Neuroimmunology Reports
- Vol. 7
Chronic levamisole-induced leukoencephalopathy: Uncommon presentation of two cases with adult-onset progressive symptoms
- 6 January 2025
- Published by Elsevier in Neuroimmunology Reports
- Vol. 7
Open AccessChronic levamisole-induced leukoencephalopathy: Uncommon presentation of two cases with adult-onset progressive symptoms
- Open Access
- 4 September 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (12) , 001-002
Multiple cerebral cavernomas in linear scleroderma: an unusual association
A 30-year-old female patient presented with recurrent right-sided clonic seizures that had started at the age of 4. Concurrently, her parents noted mild hyperpigmentation, dermal atrophy, and alopecia on the left side of her forehead. She was diagnosed with en coup de sabre scleroderma (ECDS), a subtype of linear scleroderma (LS), given the absence of systemic sclerosis symptoms ([Figure 1]). A brain magnetic resonance imaging (MRI) revealed cavernomas and white matter lesions in the left cerebral hemisphere, ipsilateral to the cutaneous lesions ([Figure 2]). Localized facial scleroderma can be associated with neurological complications, as illustrated by our case involving ipsilateral brain cavernomas.[1] [2] [3] This diagnosis is presumptive, as histopathological confirmation of the lesions was not obtained. Differential diagnoses should consider small hemorrhages, potentially secondary to vasculopathy, as suggested by the susceptibility-weighted imaging (SWI) MRI findings.[4] [5] Ayrton Roberto Massaro. Leandro Tavares Lucato. GRT, MESFB, RTNLM, RBR: conceptualization, resources, and writing – original draft; SBAN, supervision; MPMM: supervision and writing – review & editing; JLP, OGPB: supervision. Received: 27 May 2024 Accepted: 21 July 2024 Article published online: 24 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 4 September 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (12) , 001-002
Open AccessMultiple cerebral cavernomas in linear scleroderma: an unusual association
A 30-year-old female patient presented with recurrent right-sided clonic seizures that had started at the age of 4. Concurrently, her parents noted mild hyperpigmentation, dermal atrophy, and alopecia on the left side of her forehead. She was diagnosed with en coup de sabre scleroderma (ECDS), a subtype of linear scleroderma (LS), given the absence of systemic sclerosis symptoms ([Figure 1]). A brain magnetic resonance imaging (MRI) revealed cavernomas and white matter lesions in the left cerebral hemisphere, ipsilateral to the cutaneous lesions ([Figure 2]). Localized facial scleroderma can be associated with neurological complications, as illustrated by our case involving ipsilateral brain cavernomas.[1] [2] [3] This diagnosis is presumptive, as histopathological confirmation of the lesions was not obtained. Differential diagnoses should consider small hemorrhages, potentially secondary to vasculopathy, as suggested by the susceptibility-weighted imaging (SWI) MRI findings.[4] [5] Ayrton Roberto Massaro. Leandro Tavares Lucato. GRT, MESFB, RTNLM, RBR: conceptualization, resources, and writing – original draft; SBAN, supervision; MPMM: supervision and writing – review & editing; JLP, OGPB: supervision. Received: 27 May 2024 Accepted: 21 July 2024 Article published online: 24 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- Open Access
- 29 December 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (12) , 1077-1083
Sjogren's syndrome: a neurological perspective
Sjogren's syndrome (SS) is a complex autoimmune disease characterized by lymphocytic infiltration of salivary and lacrimal glands, resulting in sicca symptoms. Additionally, SS presents with neurological manifestations that significantly impact the nervous system. This review aims to provide a comprehensive overview of the neurological aspects of SSj, covering both the peripheral and central nervous system involvement, while emphasizing diagnosis, treatment, and prognosis.
- 29 December 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (12) , 1077-1083
Open AccessSjogren's syndrome: a neurological perspective
Sjogren's syndrome (SS) is a complex autoimmune disease characterized by lymphocytic infiltration of salivary and lacrimal glands, resulting in sicca symptoms. Additionally, SS presents with neurological manifestations that significantly impact the nervous system. This review aims to provide a comprehensive overview of the neurological aspects of SSj, covering both the peripheral and central nervous system involvement, while emphasizing diagnosis, treatment, and prognosis.
- Open Access
- 13 October 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (11) , 1016-1017
Diffuse leptomeningeal enhancement in neurosarcoidosis-related longitudinally extensive myelitis
A 35-year-old man presented with a 1-month history of bilateral lower limb weakness and numbness. On examination, he had paraparesis with lower limbs hyperreflexia, and T5 sensory level. Magnetic resonance imaging (MRI) of the spine revealed a longitudinally extensive myelitis (LETM) with a diffuse leptomeningeal enhancement ([Figure 1]). Thorax computed tomography (CT) disclosed bilateral hilar lymphadenopathy. A transbronchial lymph node fine-needle biopsy revealed noncaseating granulomas. Considering this finding, probable neurosarcoidosis was diagnosed. Leptomeningeal involvement is a remarkable finding in neurosarcoidosis.[1] When central nervous system (CNS) involvement occurs concomitantly with a widespread leptomeningeal enhancement, sarcoidosis should be considered as a possible differential diagnosis.[2] FFA, MPMM: conceptualization, writing – original draft, writing – review & editing; JLP, OGB: conceptualization, writing – review & editing. Received: 18 April 2023 Accepted: 03 May 2023 Article published online: 13 October 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 13 October 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (11) , 1016-1017
Open AccessDiffuse leptomeningeal enhancement in neurosarcoidosis-related longitudinally extensive myelitis
A 35-year-old man presented with a 1-month history of bilateral lower limb weakness and numbness. On examination, he had paraparesis with lower limbs hyperreflexia, and T5 sensory level. Magnetic resonance imaging (MRI) of the spine revealed a longitudinally extensive myelitis (LETM) with a diffuse leptomeningeal enhancement ([Figure 1]). Thorax computed tomography (CT) disclosed bilateral hilar lymphadenopathy. A transbronchial lymph node fine-needle biopsy revealed noncaseating granulomas. Considering this finding, probable neurosarcoidosis was diagnosed. Leptomeningeal involvement is a remarkable finding in neurosarcoidosis.[1] When central nervous system (CNS) involvement occurs concomitantly with a widespread leptomeningeal enhancement, sarcoidosis should be considered as a possible differential diagnosis.[2] FFA, MPMM: conceptualization, writing – original draft, writing – review & editing; JLP, OGB: conceptualization, writing – review & editing. Received: 18 April 2023 Accepted: 03 May 2023 Article published online: 13 October 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 20 September 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 117, 105861
Immune-mediated ataxias: Guide to clinicians
- 20 September 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 117, 105861
Immune-mediated ataxias: Guide to clinicians
- Open Access
- 17 October 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (08) , 867-868
Conus medullaris syndrome in Vogt-Koyanagi-Harada disease: an unusual presentation
A 25-year-old woman presented over one week with subacute flaccid paraparesis, saddle anesthesia and sphincter dysfunction, compatible with conus medullaris syndrome. Lumbar magnetic resonance imaging (MRI) ([Figure 1]) showed spinal cord edema and intense leptomeningeal enhancement. Six months after, she presented with aseptic meningitis and bilateral vision loss. Optical coherence tomography (OCT) showed bilateral exudative retinal detachments ([Figure 2]). Incomplete Vogt-Koyanagi-Harada disease (VKHD) was diagnosed based on the combination of bilateral granulomatous panuveitis and aseptic meningitis.[1] Spinal cord involvement is a frequent manifestation of neurological inflammatory diseases, and VKHD should be considered when typical eye, ear, and skin symptoms are present.[2] [3] FFA: conceptualization, visualization, writing – original draft, and writing – review & editing; MPMM: conceptualization, visualization, writing – original draft, and writing – review & editing; WF: conceptualization, visualization, writing – original draft; FMRF: visualization, writing – original draft; JLP: conceptualization and writing – review & editing; OGPB: conceptualization, visualization, writing – original draft, and writing – review & editing. Received: 26 January 2022 Accepted: 11 February 2022 Article published online: 17 October 2022 © 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 17 October 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (08) , 867-868
Open AccessConus medullaris syndrome in Vogt-Koyanagi-Harada disease: an unusual presentation
A 25-year-old woman presented over one week with subacute flaccid paraparesis, saddle anesthesia and sphincter dysfunction, compatible with conus medullaris syndrome. Lumbar magnetic resonance imaging (MRI) ([Figure 1]) showed spinal cord edema and intense leptomeningeal enhancement. Six months after, she presented with aseptic meningitis and bilateral vision loss. Optical coherence tomography (OCT) showed bilateral exudative retinal detachments ([Figure 2]). Incomplete Vogt-Koyanagi-Harada disease (VKHD) was diagnosed based on the combination of bilateral granulomatous panuveitis and aseptic meningitis.[1] Spinal cord involvement is a frequent manifestation of neurological inflammatory diseases, and VKHD should be considered when typical eye, ear, and skin symptoms are present.[2] [3] FFA: conceptualization, visualization, writing – original draft, and writing – review & editing; MPMM: conceptualization, visualization, writing – original draft, and writing – review & editing; WF: conceptualization, visualization, writing – original draft; FMRF: visualization, writing – original draft; JLP: conceptualization and writing – review & editing; OGPB: conceptualization, visualization, writing – original draft, and writing – review & editing. Received: 26 January 2022 Accepted: 11 February 2022 Article published online: 17 October 2022 © 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- Open Access
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1012-1025
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1012-1025
Open AccessImmunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
- Open Access
- 1 May 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (5) , 463-464
X-linked adrenoleukodystrophy presenting as progressive ataxia and pure cerebellar involvement
- 1 May 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (5) , 463-464
Open AccessX-linked adrenoleukodystrophy presenting as progressive ataxia and pure cerebellar involvement
- Open Access
- 1 December 2020
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 78 (12) , 797-804
A clinical approach to hypertrophic pachymeningitis
Importance: Hypertrophic pachymeningitis (HP) is a non-usual manifestation of rheumatologic, infectious, and neoplastic diseases. Etiological diagnosis is a challenge, but when made promptly it creates a window of opportunity for treatment, with the possibility of a total reversal of symptoms. Observations: HP is an inflammatory process of the dura mater that can occur as a manifestation of sarcoidosis, granulomatosis with polyangiitis, and IgG4-related disease. The HP case evaluation is extensive and includes central nervous system imaging, cerebrospinal fluid analysis, serology, rheumatologic tests, and systemic survey for other manifestations sites. After systemic investigation, meningeal biopsy might be necessary. Etiology guides HP treatment, and autoimmune disorders are treated with corticosteroids alone or associated with an immunosuppressor. Conclusion: HP is a manifestation of several diseases, and a precise etiological diagnosis is crucial because of the difference among treatments. An extensive investigation of patients with HP helps early diagnosis and correct treatment.
- 1 December 2020
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 78 (12) , 797-804
Open AccessA clinical approach to hypertrophic pachymeningitis
Importance: Hypertrophic pachymeningitis (HP) is a non-usual manifestation of rheumatologic, infectious, and neoplastic diseases. Etiological diagnosis is a challenge, but when made promptly it creates a window of opportunity for treatment, with the possibility of a total reversal of symptoms. Observations: HP is an inflammatory process of the dura mater that can occur as a manifestation of sarcoidosis, granulomatosis with polyangiitis, and IgG4-related disease. The HP case evaluation is extensive and includes central nervous system imaging, cerebrospinal fluid analysis, serology, rheumatologic tests, and systemic survey for other manifestations sites. After systemic investigation, meningeal biopsy might be necessary. Etiology guides HP treatment, and autoimmune disorders are treated with corticosteroids alone or associated with an immunosuppressor. Conclusion: HP is a manifestation of several diseases, and a precise etiological diagnosis is crucial because of the difference among treatments. An extensive investigation of patients with HP helps early diagnosis and correct treatment.